Outlook Therapeutics (OTLK) News
NASDAQ: OTLKHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
OTLK news summary
We found 2 recent headlines mentioning Outlook Therapeutics (OTLK): 2 in the past week and 2 in the past 30 days, most often from Nasdaq, GlobeNewswire. OTLK is making an outsized move today, up 6.19% at $0.5989, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer", was published by Nasdaq on Oct 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Outlook Therapeutics headlines
- Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer(RTTNews) - On Friday, Outlook Therapeutics (OTLK), a biopharmaceutical company developing and commercializing LYTENAVA for retinal diseases, announced Greg DiPasquale as Chief Commercial Officer.Nasdaq
- Outlook Therapeutics Names Greg DiPasquale Chief Commercial OfficerVeteran retina commercial leader, who has helped launch BEOVU®, EYLEA® and EYLEA® HD, to lead U.S. commercialization of LYTENAVA™ (bevacizumab-vikg) Veteran retina commercial leader, who has helped…GlobeNewswire